Novel monoclonal antibody-based therapies for multiple myeloma
13th August 2015
At the 20th Congress of the European Hematology Association (EHA), Sagar Lonial, MD, of the Winship Cancer Institute, Emory University, Atlanta, GA, discusses promising monoclonal antibodies in clinical development for the treatment of patients with multiple myeloma. Prof Lonial focuses on the basic and clinical aspects of several novel monoclonal antibodies, including daratumumab, which targets CD38, and elotuzumab, which targets signalling lymphocytic activation molecule-F7 (SLAMF7).
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?
Keep your finger on the pulseJoin Now
Elevating the Quality of Healthcare Globally